Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Jul 10:16:1590822.
doi: 10.3389/fimmu.2025.1590822. eCollection 2025.

Research progress on damage-associated molecular patterns in acute kidney injury

Affiliations
Review

Research progress on damage-associated molecular patterns in acute kidney injury

Jiajia Li et al. Front Immunol. .

Abstract

Acute kidney injury (AKI) is a clinical syndrome characterized by a sudden dysfunction of the kidney, which is common worldwide, with a relatively high incidence and mortality rate. Damage to the proximal renal tubule is a pathological hallmark of AKI, and inflammation triggered by the overactivation of the immune system is a common cause of proximal renal tubular injury, which is an important contributing factor in AKI exacerbation. Damage-associated molecular patterns (DAMPs) are endogenous molecules released by cells in response to external stimuli that can trigger an inflammatory response by binding to specific pattern recognition receptors (PRRs). Numerous studies have indicated that when the kidney is exposed to external stress or chemical stimuli, injured cells actively secrete or passively release various DAMPs, which can exacerbate or attenuate kidney injury by stimulating or inhibiting the inflammatory response through binding to the appropriate receptor. Currently, there is a lack of early diagnostic biomarkers and specific therapeutic strategies for AKI in the clinic have been established, and given the important role of the release of DAMPs in the regulation of inflammatory response, they will highly likely become favorable candidate biomarkers and clinical therapeutic targets for AKI. Therefore, a deeper understanding of the types of DAMPs and the specific mechanisms of their actions will provide more possibilities for the specific AKI diagnosis and treatment.

Keywords: AKI; DAMPs; PRRs; immunity; inflammation.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Overview of the specific functions of DAMPs in AKI through binding to different PRRs (a) HMGB1 activates RAGE, leading to downstream NF-κB signaling and inflammatory factor release. (b) Most DAMPs such as HMGB1, histones, uric acid, mtDNA, uromodulin, biglycan, LMW-HA, and S100A8/A9 activate TLR2/4/9, exacerbating the inflammatory signaling cascade. Only the downstream canonical MyD88/NF-κB signaling pathway is shown. (c) ATP regulates NLRP3 inflammasome signaling through the activation of P2X7R and subsequently promotes inflammatory responses. (d) IL-1α activates IL-1R, promoting NF-κB translocation to the nucleus and activating inflammatory signaling. (e) IL-33 activates ST2, which promotes polarization of M2 macrophages and induces the expansion of ILC2s and Tregs to fight inflammation. Meanwhile, IL-33 binds to ST2 on the surface of iNKT cells, amplifying inflammatory injury. IL-33 exhibits dual functions, which may depend on the specific immune microenvironment. Footnote: Figure 1 only shows the function of IL-1α and IL-33 as DAMPs rather their function as secreted cytokines.

Similar articles

  • Management of urinary stones by experts in stone disease (ESD 2025).
    Papatsoris A, Geavlete B, Radavoi GD, Alameedee M, Almusafer M, Ather MH, Budia A, Cumpanas AA, Kiremi MC, Dellis A, Elhowairis M, Galán-Llopis JA, Geavlete P, Guimerà Garcia J, Isern B, Jinga V, Lopez JM, Mainez JA, Mitsogiannis I, Mora Christian J, Moussa M, Multescu R, Oguz Acar Y, Petkova K, Piñero A, Popov E, Ramos Cebrian M, Rascu S, Siener R, Sountoulides P, Stamatelou K, Syed J, Trinchieri A. Papatsoris A, et al. Arch Ital Urol Androl. 2025 Jun 30;97(2):14085. doi: 10.4081/aiua.2025.14085. Epub 2025 Jun 30. Arch Ital Urol Androl. 2025. PMID: 40583613 Review.
  • Systemic Inflammatory Response Syndrome.
    Baddam S, Burns B. Baddam S, et al. 2025 Jun 20. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. 2025 Jun 20. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. PMID: 31613449 Free Books & Documents.
  • The Black Book of Psychotropic Dosing and Monitoring.
    DeBattista C, Schatzberg AF. DeBattista C, et al. Psychopharmacol Bull. 2024 Jul 8;54(3):8-59. Psychopharmacol Bull. 2024. PMID: 38993656 Free PMC article. Review.
  • Erythropoiesis-stimulating agents for preventing acute kidney injury.
    Nishiwaki H, Abe Y, Suzuki T, Hasegawa T, Levack WM, Noma H, Ota E. Nishiwaki H, et al. Cochrane Database Syst Rev. 2024 Sep 20;9(9):CD014820. doi: 10.1002/14651858.CD014820.pub2. Cochrane Database Syst Rev. 2024. PMID: 39301879
  • Proximal tubule pannexin 1 contributes to mitochondrial dysfunction and cell death during acute kidney injury.
    Poudel N, Zheng S, Skrypnyk N, Sung SJ, Goggins E, Nash WT, Pavelec C, Yee M, Balogun I, Medina CB, Yao J, Rosin DL, Leitinger N, Ravichandran KS, Okusa MD. Poudel N, et al. Am J Physiol Renal Physiol. 2025 Jun 1;328(6):F830-F849. doi: 10.1152/ajprenal.00226.2024. Epub 2025 Apr 17. Am J Physiol Renal Physiol. 2025. PMID: 40241514 Free PMC article.

References

    1. Li S, Zhou L, Huang Y, Tang S. Emerging Frontiers in acute kidney injury: The role of extracellular vesicles. Bioactive materials. (2025) 48:149–70. doi: 10.1016/j.bioactmat.2025.02.018, PMID: - DOI - PMC - PubMed
    1. Ostermann M, Lumlertgul N, Jeong R, See E, Joannidis M, James M. Acute kidney injury. Lancet. (2025) 405:241–56. doi: 10.1016/S0140-6736(24)02385-7, PMID: - DOI - PubMed
    1. Mehta RL, Cerda J, Burdmann EA, Tonelli M, Garcia-Garcia G, Jha V, et al. International Society of Nephrology’s 0by25 initiative for acute kidney injury (zero preventable deaths by 2025): a human rights case for nephrology. Lancet. (2015) 385:2616–43. doi: 10.1016/S0140-6736(15)60126-X, PMID: - DOI - PubMed
    1. Kellum JA, Romagnani P, Ashuntantang G, Ronco C, Zarbock A, Anders HJ. Acute kidney injury. Nat Rev Dis Primers. (2021) 7:52. doi: 10.1038/s41572-021-00284-z, PMID: - DOI - PubMed
    1. Pickkers P, Darmon M, Hoste E, Joannidis M, Legrand M, Ostermann M, et al. Acute kidney injury in the critically ill: an updated review on pathophysiology and management. Intensive Care Med. (2021) 47:835–50. doi: 10.1007/s00134-021-06454-7, PMID: - DOI - PMC - PubMed

MeSH terms

LinkOut - more resources